Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells

Endocrinology

Volumn 149, Issue 8, 2008, Pages 4158-4167

  Miller, Matthew ^a   Chen, Shenglin ^a   Woodliff, Jeffrey ^a   Kansra, Sanjay ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CURCUMIN; CYCLIN D3; GROWTH HORMONE; PROLACTIN; RETINOBLASTOMA PROTEIN; SERINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; HORMONE DETERMINATION; HORMONE RELEASE; HORMONE SYNTHESIS; HYPOPHYSIS TUMOR; NONHUMAN; PRIORITY JOURNAL; PROLACTIN SECRETING CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BROMOCRIPTINE; CELL PROLIFERATION; CLONE CELLS; CURCUMIN; CYCLIN D3; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; PHOSPHORYLATION; PITUITARY HORMONES; PITUITARY NEOPLASMS; PROLACTINOMA; RATS; RETINOBLASTOMA PROTEIN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 47949101098     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-1760     Document Type: Article

References (56)

1. Colao A, Lombardi G 1998 Growth-hormone and prolactin excess. Lancet 352:1455-1461
2. Gillam MP, Molitch ME, Lombardi G, Colao A 2006 Advances in the treatment of prolactinomas. Endocr Rev 27:485-534
3. Matsuyama J, Eshima N, Fukunaga T, Hori S, Kobayashi H, Isono M 2003 Various risks of osteoporosis in patients with pituitary adenomas. J Bone Miner Metab 21:91-97
4. Biller BM 1999 Hyperprolactinemia. Int J Fertil Womens Med 44:74-77
5. Naidoo U, Goff DC, Klibanski A 2003 Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 28(Suppl 2):97-108
6. Tworoger SS, Hankinson SE 2006 Prolactin and breast cancer risk. Cancer Lett 243:160-169
7. Elster AD 1993 Modern imaging of the pituitary. Radiology 187:1-14
8. Scheithauer BW, Laws Jr ER, Kovacs K, Horvath E, Randall RV, Carney JA 1987 Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol 4:205-211
9. Stergiopoulos SG, Stratakis CA 2003 Human tumors associated with Carney complex and germline PRKAR1A mutations: a protein kinase A disease! FEBS Lett 546:59-64
10. Boikos SA, Stratakis CA 2006 Pituitary pathology in patients with Carney complex: growth-hormone producing hyperplasia or tumors and their association with other abnormalities. Pituitary 9:203-209
11. Jaffrain-Rea ML, Petrangeli E, Lubrano C, Minniti G, Di Stefano D, Sciarra F, Frati L, Tamburrano G, Cantore G, Gulino A 1998 Epidermal growth factor binding sites in human pituitary macroadenomas. J Endocrinol 158:425-433
12. Ezzat S, Zheng L, Winer D, Asa SL 2006 Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. Mol Endocrinol 20:2965-2975
13. Ben-Jonathan N, Hnasko RM 2001 Dopamine as a prolactin inhibitor. Endocr Rev 22:724-763
14. Freeman ME, Kanyicska B, Lerant A, Nagy G 2000 Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523-1631
15. Kelly MA, Rubinstein M, Asa SL, Zheng G, Saez C, Bunzow JR, Allen R, Hnasko RM, Ben-Jonathan N, Grandy DK, Low MJ 1997 Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 19:103-113
16. 2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 19:115-126
17. Molitch ME 2005 Pharmacologic resistance in prolactinoma patients. Pituitary 8:43-52
18. Molitch ME 2003 Dopamine resistance of prolactinomas. Pituitary 6:19-27
19. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P 1996 Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 135:413-420
20. Olafsdottir A, Schlechte J 2006 Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2:552-561
21. Srimal RC, Dhawan BN 1973 Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 25: 447-452
22. Arora RB, Kapoor V, Basu N, Jain AP 1971 Anti-inflammatory studies on Curcuma longa (turmeric). Indian J Med Res 59:1289-1295
23. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB 1999 Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity. J Immunol 163:3474-3483
24. Corson TW, Crews CM 2007 Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130:769-774
25. Singh S, Aggarwal BB 1995 Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem 270:24995-25000
26. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Muller M, Mackman N, Ziegler R, Nawroth PP 1997 The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-κB. Thromb Haemost 77:772-782
27. Brouet I, Ohshima H 1995 Curcumin, an anti-tumour promoter and antiinflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 206:533-540
28. Korutla L, Kumar R 1994 Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim Biophys Acta 1224: 597-600
29. Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G 2007 Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 73:1024-1032
30. Hahm ER, Gho YS, Park S, Park C, Kim KW, Yang CH 2004 Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis. Biochem Biophys Res Commun 321:337-344
31. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY 2001 Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895-2900
32. Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, Takahashi A, Takahashi S, Kato S, Suzuki T, Ishioka C, Iwabuchi Y, Shibata H 2006 Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 5:2563-2571
33. Syng-Ai C, Kumari AL, Khar A 2004 Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol Cancer Ther 3:1101-1108
34. Kansra S, Yamagata S, Sneade L, Foster L, Ben Jonathan N 2005 Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 239:27-36
35. Hnasko RM, Khurana S, Shackleford N, Steinmetz R, Low MJ, Ben-Jonathan N 1997 Two distinct pituitary cell lines from mouse intermediate lobe tumors: a cell that produces prolactin-regulating factor and a melanotroph. Endocrinology 138:5589-5596
36. Klein SB, Fisher GJ, Jensen TC, Mendelsohn J, Voorhees JJ, Elder JT 1992 Regulation of TGF-α expression in human keratinocytes: PKC-dependent and -independent pathways. J Cell Physiol 151:326-336
37. Iaccarino C, Samad TA, Mathis C, Kercret H, Picetti R, Borrelli E 2002 Control of lactotrope proliferation by dopamine: essential role of signaling through D2 receptors and ERKs. Proc Natl Acad Sci USA 99:14530-14535
38. Jee SH, Shen SC, Tseng CR, Chiu HC, Kuo ML 1998 Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J Invest Dermatol 111:656-661
39. Kamat AM, Sethi G, Aggarwal BB 2007 Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in IFN-α-sensitive and IFN-α-resistant human bladder cancer cells. Mol Cancer Ther 6:1022-1030
40. Collett GP, Campbell FC 2004 Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25:2183-2189
41. Jiang MC, Yang-Yen HF, Lin JK, Yen JJ 1996 Differential regulation of p53, c-Myc, Bcl-2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells. Oncogene 13:609-616
42. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB 2002 Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 23:143-150
43. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB 2002 Curcumin-induced suppression of cell proliferation correlates with downregulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 21:8852-8861
44. Jirawatnotai S, Aziyu A, Osmundson EC, Moons DS, Zou X, Kineman RD, Kiyokawa H 2004 Cdk4 is indispensable for postnatal proliferation of the anterior pituitary. J Biol Chem 279:51100-51106
45. Watters JJ, Chun TY, Kim YN, Bertics PJ, Gorski J 2000 Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells. Mol Endocrinol 14:1872-1881
46. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee W, Lee EYHP 1994 Heterozygous Rb-1/+ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9:1021-1027
47. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA 1992 Effects of an Rb mutation in the mouse. Nature 359:295-300
48. Donangelo I, Marcos HP, Araujo PB, Marcondes J, Filho PN, Gadelha M, Chimelli L 2005 Expression of retinoblastoma protein in human growth hormone-secreting pituitary adenomas. Endocr Pathol 16:53-62
49. Yoshino A, Katayama Y, Ogino A, Watanabe T, Yachi K, Ohta T, Komine C, Yokoyama T, Fukushima T 2007 Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas. J Neurooncol 83:153-162
50. 1/S cyclin-dependent kinases. J Biol Chem 272: 12738 -12746
51. Yu B, Lane ME, Pestell RG, Albanese C, Wadler S 2000 Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein. Mol Cell Biol Res Commun 3:352-359
52. Connell-Crowley L, Harper JW, Goodrich DW 1997 Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 8:287-301
53. Srivastava RK, Chen Q, Siddiqui I, Sarva K, Shankar S 2007 Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1). Cell Cycle 6:2953-2961
54. 1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70:700-713
55. Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R 2005 Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 104:879-890
56. Bharti AC, Donato N, Singh S, Aggarwal BB 2003 Curcumin (diferuloyl-methane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101:1053-1062